We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+13.47%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.57B
AUM Growth
+$553M
Cap. Flow
+$342M
Cap. Flow %
9.57%
Top 10 Hldgs %
49.57%
Holding
170
New
38
Increased
32
Reduced
29
Closed
33
Avg Time Held Equity + Options
4.4 quarters
Top 10 Avg Time Held Equity + Options
5.6 quarters
Top 20 Avg Time Held Equity + Options
4.8 quarters
Avg Time Held Equity only
4.7 quarters
Top 10 Avg Time Held Equity only
5.6 quarters
Top 20 Avg Time Held Equity only
4.9 quarters

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$104M
2
BHVN icon
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$79.7M
3
ASND icon
Ascendis Pharma A/S
ASND
+$55.2M
4
YARW
Yarrow Bioscience
YARW
+$54M
5
FOLD icon
Amicus Therapeutics
FOLD
+$32.5M

Top Sells

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$58.5M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$32.9M
3
ISRG icon
Intuitive Surgical
ISRG
+$25.4M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$24.2M
5
ZBH icon
Zimmer Biomet
ZBH
+$24.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.46%
2 Miscellaneous 1.79%
3 Consumer Staples 0.67%
4 Consumer Discretionary 0.06%
5 Industrials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ZLAB icon
151
Zai Lab
ZLAB
$2.59B
– –
-175,000
Closed -$3.71M –
LUMO icon
152
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-50,000
Closed -$3.65M –
DCPH icon
153
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-102,500
Closed -$2.32M –
ARAV
154
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-248,027
Closed -$3.27M –
ACER
155
DELISTED
Acer Therapeutics Inc
ACER
– –
-150,000
Closed -$2.09M –
SPPI
156
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-32,154
Closed -$609K –
ATRS
157
DELISTED
Antares Pharma, Inc.
ATRS
– –
-3,745,662
Closed -$7.45M –
ZSAN
158
DELISTED
Zosano Pharma Corporation
ZSAN
– –
-714
Closed -$260K –
VCRA
159
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
– –
-35,169
Closed -$1.06M –
NEOS
160
DELISTED
Neos Therapeutics, Inc
NEOS
– –
-300,000
Closed -$3.06M –
OXFD
161
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
– –
-500,356
Closed -$6.99M –
PFNX
162
DELISTED
Pfenex Inc.
PFNX
– –
-519,773
Closed -$1.38M –
TSRO
163
DELISTED
TESARO, Inc.
TSRO
– –
-129,372
Closed -$10.7M –
KERX
164
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-83,386
Closed -$388K –
JUNO
165
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-300,000
Closed -$93K –
SCMP
166
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
– –
-40,062
Closed -$719K –
RXDX
167
DELISTED
Ignyta, Inc.
RXDX
– –
-30,211
Closed -$807K –
3 4 5 6
7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2018 Portfolio in Review

As of Q1 2018, Perceptive Advisors held 170 positions worth $3.57B, up 18% from $3.02B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors deployed $342M of net new capital in Q1 2018, opening 38 new positions and adding to 32 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was AnaptysBio, an estimated $58.5M trimmed.

  • Perceptive Advisors's largest Q1 2018 buy was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.
  • Perceptive Advisors added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018, an estimated $79.7M increase.
  • Perceptive Advisors's biggest Q1 2018 reduction was AnaptysBio, cutting an estimated $58.5M.
  • Perceptive Advisors fully exited Zimmer Biomet in Q1 2018, selling an estimated $24.1M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $3.57B portfolio in Q1 2018.
  • Perceptive Advisors opened 38 new positions and closed 33 in Q1 2018.
  • Perceptive Advisors's portfolio value rose 18% quarter-over-quarter to $3.57B.

Based on Perceptive Advisors's 13F filing for Q1 2018, filed 15 May 2018.